Design, Synthesis, and Biological Evaluation of 2-Arylaminopyrimidine Derivatives as Dual Cathepsin L and JAK Inhibitors for the Treatment of Acute Lung Injury

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL Journal of Medicinal Chemistry Pub Date : 2024-12-19 DOI:10.1021/acs.jmedchem.4c02030
Chunwei Shen, Zhengtong Mao, Tianpeng Chen, Yingying Wei, Tao Zhou, Ningyuan Zhong, Gaoyang Zhu, Qiwen Shi, Zheyu Xie, Huajun Zhao, Xingxian Zhang
{"title":"Design, Synthesis, and Biological Evaluation of 2-Arylaminopyrimidine Derivatives as Dual Cathepsin L and JAK Inhibitors for the Treatment of Acute Lung Injury","authors":"Chunwei Shen, Zhengtong Mao, Tianpeng Chen, Yingying Wei, Tao Zhou, Ningyuan Zhong, Gaoyang Zhu, Qiwen Shi, Zheyu Xie, Huajun Zhao, Xingxian Zhang","doi":"10.1021/acs.jmedchem.4c02030","DOIUrl":null,"url":null,"abstract":"Acute lung injury (ALI) is a disease characterized by pulmonary inflammation, blood barrier functional disorder, and hypoxemia. Herein, a series of 2-aminopyrimidine derivatives were synthesized. Most of them exhibited inhibitory effects on inflammatory cytokines IL-6 and IL-8 in human bronchial epithelial (HBE) cells at a concentration of 5 μM without significant cytotoxicity. Compound <b>A8</b> displayed an excellent anti-inflammatory activity, achieving inhibition rates of 83% for IL-6 and 85% for IL-8. Besides, <b>A8</b> has a strong binding affinity to CTSL and a good inhibitory activity on JAKs. Western blot analysis indicated that compound <b>A8</b> strongly blocked the maturation of CTSL and the phosphorylation of p-38, p-65, and STATs, thereby repressing the activation of the MAPK, NF-κB, and JAK/STAT signaling pathway. Moreover, animal experiments showed that <b>A8</b> played a protective and therapeutic role in ALI in mice, validating its potential as a treatment for ALI.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"31 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02030","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Acute lung injury (ALI) is a disease characterized by pulmonary inflammation, blood barrier functional disorder, and hypoxemia. Herein, a series of 2-aminopyrimidine derivatives were synthesized. Most of them exhibited inhibitory effects on inflammatory cytokines IL-6 and IL-8 in human bronchial epithelial (HBE) cells at a concentration of 5 μM without significant cytotoxicity. Compound A8 displayed an excellent anti-inflammatory activity, achieving inhibition rates of 83% for IL-6 and 85% for IL-8. Besides, A8 has a strong binding affinity to CTSL and a good inhibitory activity on JAKs. Western blot analysis indicated that compound A8 strongly blocked the maturation of CTSL and the phosphorylation of p-38, p-65, and STATs, thereby repressing the activation of the MAPK, NF-κB, and JAK/STAT signaling pathway. Moreover, animal experiments showed that A8 played a protective and therapeutic role in ALI in mice, validating its potential as a treatment for ALI.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2-芳基氨基嘧啶衍生物作为组织蛋白酶L和JAK抑制剂治疗急性肺损伤的设计、合成和生物学评价
急性肺损伤(ALI)是一种以肺部炎症、血液屏障功能障碍和低氧血症为特征的疾病。本文合成了一系列2-氨基嘧啶衍生物。在浓度为5 μM时,大多数对人支气管上皮细胞(HBE)炎症因子IL-6和IL-8有抑制作用,但无明显细胞毒性。化合物A8表现出优异的抗炎活性,对IL-6和IL-8的抑制率分别为83%和85%。此外,A8对CTSL具有较强的结合亲和力,对JAKs具有良好的抑制活性。Western blot分析表明,化合物A8强烈阻断CTSL的成熟和p-38、p-65和STATs的磷酸化,从而抑制MAPK、NF-κB和JAK/STAT信号通路的激活。此外,动物实验表明,A8对小鼠ALI具有保护和治疗作用,验证了其治疗ALI的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
文献相关原料
公司名称
产品信息
索莱宝
Methyl thiazolyl tetrazolium (MTT)
索莱宝
Methyl thiazolyl tetrazolium (MTT)
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
期刊最新文献
Modular Synthesis of Bioactive Selenoheterocycles for Efficient Cancer Therapy via Electrochemical Selenylation/Cyclization Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability Systematic All-Hydrocarbon Stapling Analysis for Cecropin A Generates a Potent and Stable Antimicrobial Peptide Preclinical Evaluation and First-in-Human PET Study of Al18F-Labeled Biphenyl-Based Dimeric PSMA Tracers Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1